

CURRICULUM VITAE

KENNETH S. HERSHON, M.D.

June 2015

North Shore Diabetes & Endocrine Associates
3003 New Hyde Park Road
Suite 201

New Hyde Park, New York 11042

(516) 327-0850

1981 - Present Partner at North Shore Diabetes & Endocrine Associates

1990 - Present Director of Research at North Shore Diabetes & Endocrine Associates

PERSONAL DATA:

Date of Birth: October 18, 1948

Cell Telephone: 516-695-6993

Internet Address: khershon@nsdea.com

EDUCATION:

Undergraduate: Brown University, B.S., Chemistry, 1970

Graduate: University of California, Berkeley, M.S.
Chemistry, 1972

Medical School: Albert Einstein College of Medicine, M.D., 1976

POSTGRADUATE TRAINING:

Internship: Mount Sinai Hospital, New York, New York
1976-1977

Residency: Mount Sinai Hospital, New York, New York
Internal Medicine, July 1977 - June 1979

Fellowship: University of Washington, Seattle, Washington
Endocrinology and Metabolism, July 1979 - June 1981

HONORS:

Magna Cum Laude Brown University

Sigma Xi Honor Society Brown University

Alpha Omega Alpha Albert Einstein

BOARD CERTIFICATIONS:

Internal Medicine: 09/12/79
Endocrinology & Metabolism: 11/10/81

AFFILIATIONS:

Long Island Jewish Medical Center, New Hyde Park, NY
North Shore University Hospital, Manhasset, NY

LICENSURE:

Washington State
September 1977 New York State #132064

ACADEMIC APPOINTMENTS:

Assistant Clinical Professor of Medicine at Albert Einstein College of Medicine –
2000 to present
Assistant Clinical Professor of Medicine at Hofstra University
2011 to present

PROFESSIONAL ORGANIZATION AND SOCIETIES:

American Association of Clinical Endocrinologist: New York State Board member
2011 to present
American Association of Clinical Endocrinologists: Chairman, Lower New York State Chapter
1990-2011
American Association of Clinical Endocrinologists: Board of Directors (National) –
2002-2005
American College of Physicians: Member
American Medical Association: Member
American Diabetes Association: Member
Fellow American College of Endocrinology
Fellow Society of Clinical Densitometry
Fellow of the American College of Physicians – American Society of Internal Medicine
American Association of Clinical Endocrinologists: Former Chairman of the Clinical Research
Committee

CONSULTANT:

Merck & Co. Inc.:	Diabetes Education and Lipid Consultant
Bristol-Myers Squibb:	Diabetes Education Consultant
Aventis	Diabetes and Osteoporosis Consultant
Advanced Tissue Science:	Diabetic Foot Ulcer Consultant
Warner Lambert:	Diabetes Consultant
Eli Lilly	Diabetes and Growth Hormone Consultant
SmithKline Beecham	Rosiglitazone Consultant
Parke-Davis	Regional Consultant Vascular Biology
Takeda	Diabetes Consultant
Novartis	Diabetes Consultant
Pfizer	Diabetic Lipid Consultant
Monarch	Vascular Biology Consultant
Wyeth-Ayerst	Vascular Biology Consultant
Otsuka	Vascular Biology Consultant
Proctor & Gamble	Osteoporosis Consultant
National Diabetes Education Initiative	Consultant
Vascular Biology Workshop	Consultant
Coach Core Curriculum	Diabetes Consultant

PUBLICATIONS:

Hershon, Kenneth. "Mechanistic Effects of the Renin-Angiotensin-Aldosterone System (RAAS) Blockade in the Prevention of Diabetes." *Endocrine Practice*. 17.May/June (2011): 430-440. Print.

Saloranta, Carola, Kenneth Hershon, Michelle Ball, Sheila Dickinson, and David Holmes. "Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia." *Journal of Clinical Endocrinology & Metabolism*. 87.9

Clinical Commentaries on Hypertension and CV Risk Management, Kenneth Hershon acknowledged as faculty for this continuing educational activity. Jointly sponsored by the New York Medical College and the Continuing Education Alliance.

Coalition for the Advancement of Cardiovascular Health Risk Watch Newsletter based on Faculty Presentations, Diabetes Consult by Kenneth S. Hershon jointly sponsored by University of Maryland School of Medicine and MEDCON. From a presentation reviewing data on CVD mortality rate in metabolic syndrome is near level of diabetes

Kenneth S. Hershon, Thomas Blevins, Christy May, Ralf Rosskamp: Once- Daily Insulin Glargine Compared with Twice-Daily NPH Insulin in Patients with Type-1 Diabetes. Published in *Endocrine Practice* 2004; 10(no.1)

Carola, Saloranta, Kenneth Hershon, Michele Ball, Sheila Dickinson and David Holmes:

Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia. Published in The Journal of Clinical Endocrinology & Metabolism 87(9): 4171-4176, 2002.

James LaSalle, Ken Hershon, Lance Berman, Eric Gibson, David Gillen, Jaman Maroni; Utility of amlodipine/atorvastatin single-pill therapy in patients with diabetes mellitus: results from the Gemini study. Abstract European Association in the Study of Diabetes, 2004.

Hershon, K.S., Bruzzone, C., Bierman, E.L., Ensinck, J.: Effect of naloxone and sodium salicylate on the acute insulin response of Chlorpropamide alcohol flush positive vs. negative non-insulin dependent diabetes (NIDDM). June 1981 (presented at 41st Annual Meeting of American Diabetes Association). Published in Diabetes Care, July-August 1982.

Hershon, K.S., Bruzzone, C., Bierman, E.L., Ensinck, J.: Effect of naloxone and sodium salicylate on the acute insulin response of chlorpropamide alcohol flush positive v. negative non-insulin dependent diabetes (NIDDM). June 1981 (submitted to Diabetes Care for publication).

Hershon, K.S., Brunzell, J., Albers, J., Hass, L., Motulsky, A.: HyperapoB-emia with variable lipid phenotype (Familial Combined Hyperlipidemia). June 1981 (submitted to the American Heart Association 54th Scientific Session).

Hershon, K.S., Kelly, W.A., Shaw, C.M., Schwartz, R.B., and Bierman, E.L.: Prolactinomas as part of the multiple endocrine neoplasia syndrome Type I. American Journal of Medicine, Vol. 74 713-720 April 1983.

Shabsigh, S., Barada, J.H., Eid, J.F., Gesundheit, N., Hershon, K.S., Place, V.A., Romas, N.A., Spivack, A.P. and the VIVUS-MUSE Study Group, VIVUS, Inc., Menlo Park, CA.: Treatment Of Erectile Dysfunction (Impotence) With Transurethral Alprostadil: Effects Of Hypertension And AntiHypertensive Medication on Outcome.

Accepted by the American Society of Hypertension as a poster presentation on May 17, 1996. Published in the American Journal of Hypertension, Vol. 9, No. 5, Part II.

Norwood, P.C., Block, M.B., Bookin, S., Decherney, G.S., Heatley, S.A. Hershon, K.S., Kaiser, F.E. Rosenblatt, S., Rosenstock, J., Gesundheit, N., Spivack, A.P. Stephens, D.E., Tam, P.Y. Place, V.A., and the VIVUS-Muse Study Group, Menlo Park, CA.: Multicenter Double-blind, Placebo-controlled Trial of Transurethral Alprostadil in Diabetic and Nondiabetic Men with Chronic Erectile Dysfunction (Impotence) (Abstract submitted to the American Diabetes's Association's 1996 meeting)

Gentzkow, G., Iwasaki, S., Haynie, K., Hershon, K., Lipkin, S., Steed, D., Mengel, M., Prendergast, J.J., Ricotta, J.: Decreased Recurrence of Diabetic Foot Ulcers After Healing by Cultured Human Dermis. Presented to the Clinical Symposium on Wound Management, Sept 7-9, 1995. Also will be presented at Wound Healing Society in Boston, May 19-24, 1996. (submitted to Symposium on Advance Wound Care)

Gentzkow,G., Iwasaki,S., Haynie,K., Hershon,K.S., Lipkin,S., Steed,D., Mengel,M., Prendergast,J.J., Ricotta,,J.,: Paper on Wound Healing Pilot Study Data for Advanced Tissue Sciences published in Diabetes Care April ed. 1996.

Harin Padma-Nathan,M.D., Wayne J.G.Hellstrom,M.D.,Fran E. Kaiser,M.D., Richard F. Labasky, M.D., Tom F. Lue,M.D., Wolfram E. Nolten,M.D., Paul C. Norwood,M.D., Craig A. Peterson, M.S., Ridwan Shabsigh, M.D., Peter Y. Tam, B.S., Virgil A. Place, M.D., and Neil Gesundheit, M.D., M.P.H.,For the Medicated Urethral System For Erection (MUSE) Study Group* - *The members of the MUSE study group are listed in the appendix (Investigators and Coordinators - K.S. Hershon,M.D., Lois Lazerson, M.S.,CCRC:Treatment Of Men With Erectile Dysfunction With Transurethral Alprostadil; Published in The New England Journal of Medicine, Vol. 336, No. 1, Jan.2 1997.

Kenneth S. Hershon, M.D., Peter Hershon – “Primary, Secondary, Tertiary and Quarternary Treatment With Troglitazone in Type 2 Diabetes Mellitus” Original article: Published in Jan/Feb 2000 issue of Endocrine Practice. vol 6, number 1, p. 20-25

Barry I. Freedman, Jean-Paul Wuerth, Kenneth Cartwright, Raymond P. Bain, Stephen Dippe, Kenneth Hershon, Arshag Mooradian and Bruce S. Spinowitz – abstract entitled “Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type II Diabetic Nephropathy (ACTION II)

C. Saloranta, D. Holmes, M. Ball, S. Dickinson and K. Hershon – abstract entitled “Efficacy and Safety of Nateglinide in Patients With Mild Hyperglycaemia” – ADA and EASD 2001

Kenneth Hershon, Tom Blevins, David Donley and Christy Littlejohn – abstract entitled “Lower Fasting Blood Glucose (FBG) and Less Symptomatic Hypoglycemia with QD Insulin Glargine (Lantus) Compared to BID NPH in Subjects with Type 1 Diabetes” – 2001 The American Diabetes Association 61st Scientific Sessions

K. Hershon, T. Blevins, D. Donley and C. Littlejohn – abstract entitled “Beneficial Effects of Insulin Glargine Compared to NPH in Subjects with Type 1 Diabetes” – European Association for the Study of Diabetes (EASD) 2001

C. Saloranta, K. Hershon, M. Ball, S. Dickinson and D. Holmes – abstract entitled “Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia” – 2002 The Journal of Clinical Endocrinology & Metabolism

J. Rosenstock, D. Einhorn, K. Hershon, N.B. Glazer, S. Yu, The Pioglitazone 014 Study Group – Original paper entitled “ Efficacy and Safety of Pioglitazone in Type 2 Diabetes: A Randomized, Placebo-Controlled Study in Patients Receiving Stable Insulin Therapy” – International Journal of Clinical Practice: May 2002 Vol. 56, No. 4

Hershon, K., Blevins, T., Mayo, C., Roskamp, R.: Original Article entitled "Once-Daily Insulin Glargine Compared with Twice-Daily NPH Insulin in Patients with Type 1 Diabetes" *Endocrine Practice*: January/February 2004 Volume 10 Number 1 Pages 10-17

Hollander, Priscilla A.; Blonde, Lawrence; Rowe, Richard ; Mehta E. Adi; Milburn, Joseph L.; Hershon S. Kenneth; Chaisson, Jean-Louis; Levin Seymour R. ; entitled "Efficacy and Safety of Inhaled Insulin (Exubera) Compared with Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes." Results of a 6-month, randomized comparative trial. *Diabetes Care*: Volume 27, Number 10, October 2004.

Bo Angelin, Kenneth S. Hershon, and John D. Brunzell entitled "Bile Acid Metabolism in Hereditary Forms of Hypertriglyceridemia: Evidence for an Increased Synthesis Rate in Monogenic Familial Hypertriglyceridemia" *PNAS*/August 1, 1987/vol.84/no.15/5434-5438.

Hershon, Kenneth S. "Emerging Options in Type 2 Diabetes." *Current Medical Excerpts* (2006): 7-8.

öke B, Hershon K, Kerr D, Pascual C, Schweizer A, Foley J, Shao Q and Dejager S. Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with metformin. *Horm Metab Res*. 2008 Aug 22. [Epub ahead of print]

Rosenstock, Julio. "Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients with Type 2 Diabetes." *Diabetes Care* 30(2007): 7. (investigator in trial)

Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team Barzilay J, Braithwaite S, Cheatham WW, Crandell J, Dandona P, Desouza C, Donovan D, Hershon K, Mazzone T, McGill J, Roberts VL, Umpierrez G, Warren W, Wittlin S, Wyne K. "The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial." *Ann Internal Medicine*. (2010): 346-357. Print.

Carola Saloranta, Kenneth Hershon, Michele Ball, Sheila Dickinson and David Holmes, . "Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia." *Journal of Clinical Endocrinology & Metabolism* . Vol. 87.Vol. 87 (2002): Print.

Hershon, K. (2011). MECHANISTIC AND CLINICAL ASPECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BLOCKADE IN THE PREVENTION OF DIABETES MELLITUS AND CARDIOVASCULAR DISEASE. *ENDOCRINE PRACTICE*, 17(3).

LECTURES & PRESENTATIONS:

Rayfield, E.J., Hershon, K.S., Morgan, G., and Freeman, J.R.,: Islet Cell Surface Antibodies in Pancreatic Disease. June 1979 (presented at 39th annual meeting of American Diabetes Association).

Stolov, W.C., Fujimoto, W.Y., Hershon, K.S., and Thompson, S.C.: Neuropathy and biochemical abnormalities in Japanese and Caucasian subjects with non-insulin dependent maturity onset diabetes. September 1980 (presented at the meeting of the American Association of Electromyography and electrodiagnosis).

Fujimoto, W.J., Hershon, K.S., Kinyoun, J.L., Okamoto, J., Ring, E., Stolov, W.C., Gale, J.C.: Maturity onset diabetes in second generation Japanese Americans (Nisei) and Caucasian males in Seattle Washington: A pilot study. February 1981 (presented at the meeting of the Third Symposium on Diabetes Mellitus in Asia and Oceania).

Schmer, C., Rastelli, L., Dennis, Jr., M.D., Hershon, K.S., Young, J., Chait, A.,: Removal of low density lipoprotein in sheep by extracorporeal affinity chromatography. June 1981 sheep by extracorporeal affinity chromatography. June 1981 (presented at the meeting of the American Society for Artificial Internal Organs).

Marshall B. Block, M.D., Stephen Bookin, M.D., G. Stephen DeCherney, M.D., Kenneth S. Hershon, M.D., Wolfram E. Nolten, M.D., Paul C. Norwood, M.D., Sidney Rosenblatt, M.D., Julio Rosenstock, M.D., Julio Rosenstock, M.D., Don S. Schalch, M.D., Sherwyn L. Schwartz, M.D. - abstract entitled "Transurethral Alprostadil for the Treatment of Erectile Dysfunction in Men with Diabetes; Effect of Duration of Diabetes on Efficacy" - presented as a poster presentation at the American Diabetes Association in Boston June 21-24, 1997

June 23, 1997 - Annual ADA Meeting, Boston, Mass - Program Chairman for symposium "Late-Breaking Treatment Modalities for Type II Diabetes"

October 22, 1997 - CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine - "Perspectives on the Treatment and Prevention of Non-Insulin Dependent Diabetes Mellitus"

April 21, 1998 - Science and Medicine Lecture Series, Long Island, NY - "Insulin Resistance: Data and Dialogue"

May 20, 1998 - CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine - "Type 2 Diabetes Training - Incorporating New Treatment Modalities into Clinical Practice"

October 10, 1998 - Pfizer/Diabetes Meeting, Seattle, Washington - "Developing New Strategies for Treatment of Type 2 Diabetes"

November 14, 1998 - CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine - "Insulin Resistance Syndrome - Pathway to Glucose Control"

April 17, 1999 - Parke-Davis Diabetes Consultants' Conference - New York, New York "Insulin Resistance: The Primary Defect in Type 2 Diabetes

Philip Raskin, M.D., Glen Park M.D., Joyce Zimmerman, M.D. for the US Study Group of HOE 901 in Type 2 DM, - abstract entitled " The Effect of HOE-901 on Glycemic Control in Type 2 Diabetes" - presented in Dallas, TX and Bridgewater, NJ.

Julio Rosenstock, M.D., Glen Park, M.D., Joyce Zimmerman, M.D., for the US Study Group of HOE 901 in Type I DM - abstract entitled "Efficacy and Safety of HOE 901 in Patients with Type I DM: A Four-Week Randomized, NPH Insulin-Controlled Trial. - presented in Dallas, TX and Bridgewater, NJ.

Kenneth S. Hershon, M.D., Peter Hershon - abstract entitled "Primary, Secondary, Tertiary and Quarternary Treatment With Troglitazone in Type 2 Diabetes Mellitus" presented at the 1999 Poster Session of the American Association of Clinical Endocrinologists (AACE) Eighth Annual Meeting and Clinical Congress in San Diego, CA April 28 - May 2, 1999.

October 5, 1999 – Seminar presentation at Montefiore Medical Center – "Treatment, Advances and Update in Diabetes"

October 13, 1999 – CME Program, Long Island Jewish Medical Center/Albert Einstein College of Medicine – "New Management Strategies in Type 2 Diabetes"

November 10, 1999 – CME Program, Mount Sinai School of Medicine – "New Treatment Options in Type 2 Diabetes"

June 14, 2000 – Grand Rounds, St. Lukes-Roosevelt Hospital Center – "Lipids and Diabetes"

July 24, 2000 – Grand Rounds, Downstate Medical Center – "SERMS and Estrogen Receptors"

November 28, 2000 – Women's Wellness Program, North Shore – Long Island Jewish Health System – "Boning Up On Osteoporosis"

February 17, 2001 – CME course – New Frontiers in Diabetes Management – Approaches to achieving glycemic control – Presented at Primary Care Medical – West Long Beach California – National meeting

April 4, 2001 – CME course – Heterogenesis Etiology of type II DM - It's impact on coronary disease and mortality – North Shore Diabetes & Endocrine Associates – North Shore – Long Island Jewish Hospital System, NY

June 6, 2001 – CME course – Vascular biology workshop – Micro hope and ACE endothelial dysfunction

June 27, 2001 – CME course – Insulin in type II diabetes updated – North Shore – Long Island Jewish Hospital System, NY

June 30, 2001 – Grand Rounds – Post Prandial Hyperglycemia – Buffalo Hospital, Buffalo, NY

September 19, 2001 – Grand Rounds – Osteoporosis Update – Forest Hills Hospital, Queens, NY

September 30, 2001 – CME course – Osteoporosis Update – Nassau, Queens Medical Society, NY

November 17, 2001 – CME course –Core Curriculum – Micro Hope – ACE endothelial dysfunction, Nappa Valley, CA

December 1, 2001 – CME course – Micro Hope – ACE endothelial dysfunction – Kansas City

December 8, 2001 – CME course – Micro Hope – ACE endothelial dysfunction – Farmington, PA

December 15, 2001 – CME course – Micro Hope – ACE endothelial dysfunction – Rancho Mirage, CA

January 9, 2002 – CME course – Update on diabetes – Vytra – North Shore – Long Island Jewish Hospital System, NY

February 23, 2002 – CME course – The Cardiodynamics of Diabetes Control – Louisville, Kentucky

March 23, 2002 – CME courses – The Cardiodynamics of Diabetes Control – St. Paul, Minnesota

April 22, 2002 – CME course – Fracture Prevention: The Goal for Postmenopausal Osteoporosis Management – Garden city New York

May 11, 2002 – CME course – The Cardiodynamics of Diabetes Control – Scottsdale, Arizona

June 15, 2002 – CME course – The Cardiodynamics of Diabetes Control – Buffalo, NY

June 22, 2002 – CME course – The Cardiodynamics of Diabetes Control – Greenville, South Carolina

August 3, 2002 – CME course – The Cardiodynamics of Diabetes Control – Birmingham, Alabama

December 4, 2002 – CME course – CV Risk Reduction – Great Neck, New York

December 5, 2002 – CME course – CV Risk Reduction – Hackensack, New Jersey

January 24, 2003 – CME course – Redefining Clinical Practice Patterns for Cardiovascular Risk Reduction – Torrington, Connecticut

February 15, 2003 – CME course – Individualizing Osteoporosis Treatments – Roslyn, New York

March 13, 2003 – Grand Rounds – “Redefining Clinical Practice Patterns for Cardiovascular Risk Reduction – New York, New York

March 15, 2003 – CME course – Diabetes and CV Disease: Risk equivalents and strategies for treating the total patient – Richmond, Virginia

April 12, 2003 – CME course – The Diabetic: It is sooner than you think – Kansas City, Missouri

May 10, 2003 – CME course - The Diabetic: It is sooner than you think – Fort Lauderdale, Florida

May 15, 2003 – CME course – The Evolution of Clinical Research in Endocrine Practice – AACE Annual meeting – San Diego, California

May 17, 2003 – CME course – The Diabetic: It is sooner than you think – Chicago, Illinois

May 18, 2003 – CME course – Diabetic Management, an Interactive/Shared Responsibility – Jericho, New York

June 14, 2003 – CME course – The Role of Pharmacotherapy in the Treatment of Dysmetabolic Syndrome – Where Does Diabetes Start? When Should Treatment Start” – New York, New York

June 18, 2003 – Grand Rounds – “Insulin Resistance and CV Disease” – Catholic Medical Center – Manchester, New Hampshire

June 21, 2003 – CME course – The diabetic: It is sooner than you think – Garden City, New York

June 28, 2003 – CME course – The diabetic: It is sooner than you think – Hot Springs, Arkansas

July 12, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – San Jose, California

August 2, 2003 – CME course – The diabetic – It is sooner than you think – Jackson, Mississippi

August 9, 2003 – CME course – The diabetic – It is sooner than you think – Woodstock, Vermont

September 6, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – New Orleans, Louisiana

September 13, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – Chicago, Illinois

September 18, 2003 – Grand Rounds - Intensive Management of Diabetes – Metropolitan Hospital Center – New York, NY

October 4, 2003 – CME course – The diabetic: It is sooner than you think – St. Louis, Missouri

October 18, 2003 – CME course – Diabetes and CV disease: Risk equivalents and strategies for treating the total patient – Philadelphia, PA

October 25, 2003 – CME course – The diabetic: It is sooner than you think – Denver, Colorado

November 8, 2003 – CME course – The diabetic: It is sooner than you think – New Paltz, New York

November 15, 2003 – CME course – The diabetic: It is sooner than you think – Chapel Hill, North Carolina

November 22, 2003 – CME course – The diabetic: It is sooner than you think – St. Paul, Minnesota

January 14, 2004 – Grand Round – Post-intervention continuum of care: Focus on lipid management in acute and long-term settings. – Bergen Regional Medical Center, Paramus, NJ

April 1, 2004 – Grand Rounds – Treating Type 2 Diabetes Mellitus – The New Paradigm – Winthrop University Hospital, Mineola, NY

April 17, 2004 – CME course – Cardiorenal protection in the diabetic patient: New data – Seattle, Washington

May 1, 2004 – CME course – Cardiorenal protection in the diabetic patient: New Data – New York, New York

May 20, 2004 – CME course – Blunting the atherosclerotic process: The case for aggressive lipid management – Savannah, Georgia

May 22, 2004 – CME course – CV risk reduction in high risk patients: Strategies for prevention – Cleveland, Ohio

June 9, 2004 – CME course – From Bench to bedside: Achieving lipid goals in daily practice – Cincinnati, OH

June 11, 2004 – CME course – Concurrent Hypertension And Dyslipidemia: Multiplied Risk for CVD – Norfolk, VA

June 26, 2004 – CME course – Interpreting new trial data in multiple risk patients – Orlando, FL

July 24, 2004 – CME course – Improving outcomes in the metabolic syndrome patient: Targeted approach to CV risk reduction – Palm Beach, FL

September 9, 2004 – CME course – Vascular biology of CV risk: Benefits of multiple risk factor intervention – Washington, DC

September 18, 2004 – CME course – Improving outcomes in the metabolic syndrome patient: Targeted approach to CV risk reduction – Seattle, WA

October 6, 2004 – Grand Rounds – Multiple risk and cardiovascular disease prevention – Jersey City Medical Center, Jersey City, NJ

October 23, 2004 – CME course – Multifactorial intervention on macrovascular and microvascular outcomes for diabetes risk reduction: Practical insights and strategies – Atlanta, GA

December 4, 2004 - Grand Rounds- Multispecialty- Blunting the atherosclerotic process: The case for aggressive lipid management. Stormont-Vail Regional Medical Center, Topeka, Kansas

Hershon, Kenneth. "Explore online CME." Is Non-Diabetic Hyperglycemia a CVD Risk Factor? . 17 Feb 2006 . PriMed. 29 Apr 2008 <<http://www.primed.com/PMO/Activity.aspx?activity=139>>.

Hershon, Kenneth. "On Line CME Activity." The Case for Starting Insulin Therapy in Type 2 Diabetes . 22 Jul 2006. PriMed. 29 Apr 2008 <<http://www.primed.com/PMO/Activity.aspx?activity=250>>.

Hershon, Kenneth. "Explore online CME." A Critical Appraisal of the Metabolic Syndrome . 31 Oct 2006. PriMed. 29 Apr 2008 <<http://primed.com/PMO/Activity.aspx?activity=321&StepIndex=1>>.

April 29, 2009, CME program, Exploring the Dual Defects in Type 2 Diabetes: Insulin Resistance and Beta Cell Dysfunction, Summit NJ

August 29, 2009 CME course “AACE Diabetes Day for Primary Care Physicians” Novel Therapies for Type 2 Diabetes, NY, NY

September 29, 2009, CME program Macro- and Microvascular Effects of Hyperglycemia: Addressing Issues and Controversies, Forsyth Medical Center, NC

October 29, 2009, CME program Incretin Therapy: A New Paradigm in the Treatment of Type 2 Diabetes San Joaquin General Hospital, Fresh Camp, CA

Feb 9, 2010 CME course, Bisphosphonate therapy for the Management of Osteoporosis, Roslyn NY

June 12, 2010 CME course “AACE Diabetes Day for Primary Care Physicians” Novel Therapies for Type 2 Diabetes, NY, NY

June 19, 2010 CME program Insulin Therapy: Minimizing Barriers, Optimizing Treatment Phoenix, AZ

Hershon, K. (Director) (2011, July 9). Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes . 2011 Diabetes Day for Primary Care Physicians. Lecture conducted from AACE, Manhattan.

Hershon, K. (Director) (2013, November 16). Life Style Modification Therapy. Diabetes Day for Primary Care Clinicians. Lecture conducted from AACE, Manhattan.

1995-2015 between 15-20 promotional lectures per year for various pharmaceutical companies.

RESEARCH:

Co-Investigator - Diabetic Oral Agent - Upjohn.

Principal Investigator - Management of Diabetic Foot Ulcers - Zymogenetics Inc.

Principal Investigator - Diabetic Oral Agent - Hoechst

Principle Investigator - Combined Oral Agent & Insulin - Hoechst.

Consultant and Non-Healing Foot Ulcer Study Phase II

Principal Investigator - Advanced Tissue Sciences

Principal Investigator - Foot Ulcer Study - Telios

Co-Investigator - Diabetic oral agent - Roerig-Pratt

Principal Investigator - Infected Diabetic Foot Ulcers - Magainin

Principal Investigator - Achieve - Accupril in CHF - Parke-Davis

Principal Investigator - Erectile dysfunction Phase II - Vivus
Principal Investigator - Erectile dysfunction Phase III & Open-label - Vivus
Principal Investigator - Non-healing Foot Ulcer Study Phase III - Advanced Tissue Sciences -
Principal Investigator - Peripheral Arterial Occlusive Disease - Alpha Therapeutic Corporation
Principal Investigator - Diabetic Nephropathy Type II - Alteon
Principal Investigator - Diabetic Nephropathy Type I - Alteon
Principal Investigator - Diabetic Gastroparesis - Janssen Research Foundation
Principal Investigator - Essential Hypertension - Wyeth-Ayerst
Principal Investigator - Osteoporosis - Eli Lilly
Sub-Investigator - Endometrial Hyperplasia - Eli Lilly
Principal Investigator - New Insulin in IDDM - Hoechst-Roussel
Principal Investigator - New Insulin in NIDDM - Hoechst-Roussel
Principal Investigator - Osteoporosis - Merck
Principal Investigator - Diabetic Lower Extremity Ulcers - Oxford
Principal Investigator - Proteinuria - Merck
Co-Investigator - Alzheimer - Pfizer
Principal Investigator - Diabetic Oral Agent - Parke-Davis
Principal Investigator - Diabetic Oral Agent - Bayer
Principal Investigator - Diabetic Oral Agent - Takeda
Principal Investigator - Fast Acting Insulin - Novo Nordisk + Extension
Sub-Investigator - Metastatic Bone Disease - Boehringer-Mannheim
Sub-Investigator - Intravitreal Hemorrhage - Advanced Corneal Systems
Principal Investigator - CHF - Ciba (Novartis)
Principal Investigator - Fast Acting Insulin Combination - Eli Lilly
Principal Investigator - Hypopituitary - Eli Lilly
Principal Investigator - Obesity - Wyeth-Ayerst
Principal Investigator - Renal Impairment Type II Diabetics - Takeda
Principal Investigator - Hormone Patch - Wyeth-Ayerst
Principal Investigator - Hormone Patch - Ethical Pharmaceuticals
Principal Investigator - New Insulin - Type I - Hoechst Marion Roussel
Principal Investigator - New Insulin - Type II - Hoechst Marion Roussel
Principal Investigator - Erectile Dysfunction - Schiff & Co.
Principal Investigator - Diabetic Oral Agent - SmithKline Beecham Pharmaceuticals
Principal Investigator - Diabetic Oral Agent - SmithKline Beecham Pharmaceuticals
Principal Investigator - Diabetic Oral Agent & CHF - SmithKline Beecham Pharmaceuticals
Principal Investigator - Diabetic Oral Agent - Takeda America
Principal Investigator - Diabetic Oral Agent - Takeda America
Principal Investigator - Diabetic Oral Agent - Takeda America
Sub - Investigator - Genitourinary Atrophy - Eli Lilly
Principal Investigator - Diabetic Oral Agent - Bristol-Myers Squibb
Principal Investigator - Diabetic Oral Agent - Bristol-Myers Squibb
Principal Investigator - Diabetic Oral Agent - GlaxoWellcome
Principal Investigator - New Insulin - Type I - Hoechst Marion Roussel
Principal Investigator - Diabetic Oral Agent - Takeda America
Co-Investigator - Diabetic Foot Ulcer - Organogenesis
Principal Investigator - Diabetic Polyneuropathy - Pfizer

Principal Investigator - Oral Diabetic - Parke-Davis
Principal Investigator - Disposable Pen - Eli Lilly
Principal Investigator - Oral Diabetic - Novartis
Principal Investigator - Essential Hypertension - Novartis
Principal Investigator - Obesity & Diabetes - Amgen
Principal Investigator - Obesity & Diabetes - Amgen
Principal Investigator - Oral Diabetic - Bristol-Myers Squibb
Principal Investigator - Oral Diabetic (Extension) - Takeda
Principal Investigator - Hypertension (x3) - Bristol-Myers Squibb
Principal Investigator - Oral Diabetic - Parke-Davis
Principal Investigator - Obesity - Hoffman LaRoche
Principal Investigator - Inhaled Insulin (x3) - Pfizer
Principal Investigator - HRT - Berlex Labs
Co-Investigator - Diabetic Retinopathy - Eli Lilly
Co-Investigator - Diabetic Macular Edema - Eli Lilly
Principal Investigator - Flu - Hoffman LaRoche
Co Principal Investigator - Neuropathy - Parke-Davis
Principal Investigator - Obesity & Diabetes - Amgen
Principal Investigator - Oral Diabetic - Parke-Davis
Principal Investigator - Oral Diabetic - Novartis
Principal Investigator - Hyperlipidemia - SmithKline Beecham
Principal Investigator - Oral Diabetic - Takeda
Principal Investigator - Hypertriglyceridemia - Rhone-Poulenc Rorer
Sub-Investigator - Treatment Resistant Depression - Eli Lilly
Principal Investigator – Oral Diabetic (X3) – Glaxo Wellcome
Sub-Investigator – Diabetic Foot Ulcer – Ortec
Principal Investigator – Lipid Lowering – Park-Davis/Pfizer
Principal Investigator – Hypercholesterolemia – Parke-Davis/Pfizer
Principal Investigator – Oral Diabetic – Parke-Davis
Principal Investigator – Hypertension – Bristol-Myers Squibb
Principal Investigator – Insulin – Hoechst Marion Roussel
Principal Investigator – Oral Diabetic – Pharmacia & Upjohn
Principal Investigator – Painful Diabetic Neuropathy – Bristol-Myers Squibb
Principal Investigator – Oral Diabetic - Bristol-Myers Squibb
Principal Investigator – Oral Diabetic – Merck
Sub-Investigator – Diabetic Foot Ulcers – Advanced Tissue Sciences
Principal Investigator – Lipid/Diabetes – Merck
Principal Investigator – Anemia in Early Renal Insufficiency (X2) – OrthoBiotech
Principal Investigator – URI - ViroPharma
Principal Investigator – Oral Diabetic – Takeda
Principal Investigator – Oral Diabetic – Takeda
Principal Investigator – Oral Diabetic – AstraZeneca
Principal Investigator – Oral Diabetic – Pharmacia & Upjohn
Principal Investigator – Hypertension – Bristol-Myers Squibb
Principal Investigator – Oral Diabetic – Pfizer
Principal Investigator – Oral Diabetic – Novartis

Principal Investigator – Oral Diabetic – Aventis
Principal Investigator – Oral Diabetic – Insmmed
Principal Investigator – Oral Diabetic – Bristol-Myers Squibb
Principal Investigator – Oral Diabetic – Bristol-Myers Squibb
Principal Investigator – Oral Diabetic – Wyeth-Ayerst
Principal Investigator – Long Acting Insulin – Aventis
Principal Investigator – Fast Acting Insulin X2 – Aventis
Principal Investigator – Oral Diabetic – Novartis
Principal Investigator – Oral Diabetic – Bristol-Myers
Principal Investigator – Insulin – NovoNordisk
Principal Investigator – Pump X2 – Restoragen
Principal Investigator – Oral Diabetic – Novartis
Principal Investigator – Oral Diabetic – Bristol-Myers
Principal Investigator – Osteoporosis – Wyeth-Ayerst
Principal Investigator – Insulin – Aventis
Principal Investigator – Lipid/Diabetes - Merck
Principal Investigator – Inhaled Insulin - Type 1 & 2 – Pfizer
Principal Investigator – Hemoglobin-Renal Insufficiency – OrthoBiotech
Principal Investigator – Oral Diabetic – Takeda
Principal Investigator – Oral Diabetic - AstraZeneca
Principal Investigator – Hypertension/Hyperlipidemia – Pfizer
Principal Investigator – Insulin – Type 2 – Aventis
Principal Investigator – Cardiovascular – AstraZeneca
Principal Investigator – Insulin + Oral Diabetic – GlaxoSmithKline
Principal Investigator – Diabetic Hypertension – Pfizer
Principal Investigator – Inhaled Insulin – Eli Lilly
Principal Investigator – Oral Diabetic – Bristol-Myers
Principal Investigator – Oral Diabetic X2 – Bristol-Myers
Principal Investigator – Insulin Add-on – Aventis
Principal Investigator – Hyperlipidemia – Merck
Principal Investigator – Hypertension – Novartis
Principal Investigator – Oral Diabetic – Takeda X2
Principal Investigator – Oral Diabetic – Metabolex
Principal Investigator – Oral Diabetic – Novartis X 5
Principal Investigator – Inhaled Insulin – Pfizer
Principal Investigator – Oral Diabetic – GlaxoSmithKline
Principal Investigator – Lipids – Merck
Principal Investigator – Lipids – Pfizer
Principal Investigator – Oral Diabetic – AstraZeneca
Principal Investigator – Hypogonadism – Auxilium
Principal Investigator – Oral Diabetic – Takeda
Principal Investigator - Inhaled insulin- MannKind
Principal Investigator - Inhaled insulin – Eli Lilly
Principal Investigator - Renal Insufficiency (x2) – Keryx
Principal Investigator - Renal Insufficiency- Speedel
Principal Investigator - Oral Diabetic –Roche

Principal Investigator - Insulin + oral agent- Brigham and Women's Health Hospital
Co-Investigator - Diabetic Foot Ulcer- Apo Pharma
Principal Investigator - Oral Diabetic Agent- Merck
Principal Investigator - Oral Agent – NIH
Principal Investigator – Insulin (x2) Sanofi Aventis
Principal Investigator - Hypertension – Novartis
Principal Investigator – Oral Diabetic Agent- Boehringer Ingelheim
Principal Investigator – Injectable diabetic medication Amylin
Principal Investigator – Neuropathy Abbott
Principal Investigator – Hypertension- Takeda
Principal Investigator - Nephropathy- Nephrogenex
Principal Investigator- Oral Diabetic Agent- National Institute of Health
Principal Investigator- Oral Diabetic Agent-Novartis
Principal Investigator- Injectable diabetic medication- Novo Nordisk
Principal Investigator- Hypertension- Novartis
Principal Investigator- Injectable diabetic medication- Amylin
Principal Investigator- Inhaled insulin (COPD) – MannKind
Principal Investigator- Oral Diabetic Agent- Akros
Principal Investigator-Oral Diabetic Agent (x2) Forest Research
Principal Investigator- Diabetic Nephropathy-Fibrogen
Principal Investigator- Inhaled insulin (device)-MannKind
Principal Investigator- Oral Diabetic Agent- AstraZeneca
Principal Investigator- Oral Diabetic Agent-Johnson & Johnson
Principal Investigator- Insulin Delivery Device- Valeritas
Principal Investigator-Insulin for Type 1 Diabetics- Lilly
Principal Investigator-Insulin for Type 2 Diabetics- Lilly
Principal Investigator-Insulin for Type 1 Diabetics- Sanofi
Principal Investigator-Insulin for Type 2 Diabetics- Sanofi
Principal Investigator-Injectable Diabetic Medication- Sanofi
Principal Investigator-Injectable medication for Hyperlipidemia- Amgen
Principal Investigator-Oral Diabetic Agent- BristolMyers
Principal Investigator-infusible medication for insulin pump- Halozyme Therapeutics
Principal Investigator-Diabetic Nephropathy-AbbVie
Principal Investigator- MACE assessment of an Oral Diabetic Agent- AstraZeneca
Principal Investigator-Injectable Diabetic Medication-Sanofi
Principal Investigator-Injectable Diabetic Medication- Sanofi
Principal Investigator - Mace assessment of weight loss medication -Orexigen
Principal Investigator- Injectable treatment for hyperlipidemia- Amgen
Principal Investigator- Diabetic Nephropathy- Abbvie
Principal Investigator- MACE assessment of an oral diabetic Medication- AstraZeneca
Principal Investigator- MACE assessment of a weight loss medication- Esai
Principal Investigator- Insulin in elderly type 2 diabetes- Boehringer Ingelheim

